Stay updated on Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.

Latest updates to the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page
- Check5 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded the related MeSH term 'Primary interstitial lung disease specific to childhood' to the page's related topics/MeSH terms.SummaryDifference0.1%

- Check34 days agoChange DetectedThe page revision header was updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check42 days agoChange DetectedPage revision updated to v3.4.3; the previous revision v3.4.2 was superseded.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision: v3.4.2 was added and an older funding/operating-status notice was removed; these are minor administrative updates that do not affect the study content or how you interact with the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check77 days agoChange DetectedAdded a government funding lapse notice about data currency and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Doxorubicin & Pembrolizumab in Sarcoma Clinical Trial page.